Senseonics Holdings Inc.
01/12/2026 | Press release | Distributed by Public on 01/12/2026 07:26
Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update (Form 8-K)
Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update
Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year
Introduced 2026 revenue guidance of $58-$62 million
Expects to report fourth quarter and full year 2025 financial results on March 2, 2026
GERMANTOWN, Md.-January 12, 2026 (BUSINESS WIRE)-- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced preliminary revenue for the fourth quarter of 2025 and provided a general business update.
Recent Highlights & Accomplishments
| · | Generated preliminary unaudited fourth quarter 2025 revenue of approximately $14.2 million, an increase of 71% year-over-year, and preliminary unaudited revenue of approximately $35.2 million, an increase of approximately 57% year-over-year, representing largest quarterly and annual revenue in company history. |
| · | Achieved 103% new patient growth in the U.S. in the fourth quarter versus the same period in 2024, driven largely by positive returns from direct-to-consumer (DTC) marketing efforts and representing the largest new patient addition in company history. |
| · | Secured Investigational Device Exemption (IDE) approval from the FDA to commence a pivotal trial for the self-powered battery enabled Gemini sensor and enrolled the first patients in the trial. |
| · | First commercial patients using pump partner Sequel's twiist™ insulin delivery system with Eversense 365 compatibility. |
| · | Executed agreements with Ascensia Diabetes Care to take over commercialization and distribution of Eversense®, beginning January 1, 2026 in the U.S. |
"We closed a successful 2025 on a high note, achieving by far our highest revenue quarter as our DTC efforts continue to drive an increasing number of patients to the world's first and only year-long CGM, said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. "We now look ahead to a 2026 that should bring more exciting developments for Senseonics, most notably the transition of commercial and distribution rights to Eversense 365 from Ascensia, which we expect will lead to higher revenue and improved gross margins. We also expect a boost from an anticipated CE mark in Europe for Eversense 365, the launch of the twiist system with full Eversense compatibility, and the completion of the Gemini trial in the second half of 2026. Taken together, we look forward to building on the momentum we established in 2025 to drive increased shareholder value in 2026 and beyond."
Full Year 2026 Financial Outlook
Senseonics expects full-year 2026 global net revenue to be approximately $58-$62 million, representing an increase of 65% to 76% over 2025 revenue, which reflects the transition of Eversense commercialization from Ascensia effective January 1, 2026. The Company and Ascensia are continuing to finalize the agreements to transition the European sales and marketing infrastructure to Senseonics. Gross margin is expected to be approximately 50% for the full year. More detail on financial results and expectations for 2026 will be provided on the earnings call, expected to take place on March 2, 2026.
Fourth Quarter and Full Year 2025 Financial Results & Conference Call Information
The Company currently expects to report revenues of approximately $14.2 million for the fourth quarter 2025 and full year 2025 total revenue of approximately $35.2 million. The Company's unaudited balance of cash, cash equivalents and restricted cash as of December 31, 2025, is expected to be approximately $94.3 million. The preliminary financial results described in this update have not been audited and are subject to adjustment based on the Company's completion of year-end financial close processes.
Senseonics plans to release its fourth quarter and full year 2025 financial results after market close on March 2, 2026.
Management will hold a conference call to review the Company's fourth quarter and full year 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics' website at www.senseonics.com by navigating to "Investor Relations," and then "Events & Publications," and will be archived there for future reference. To listen to the conference call, please dial 1-800-343-5172 (US/Canada) or 1-203-518-9856 (International), passcode SENSQ4, approximately five to ten minutes prior to start time.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.
Senseonics Holdings Inc. published this content on January 12, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on January 12, 2026 at 13:26 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]